Examiner: CARCANAGUE, DANIEL R

Tech Center 1600 • Art Units: 1621 1625

This examiner grants 81% of resolved cases

Performance Statistics

80.9%

Allow Rate

+20.9% vs TC avg

939

Total Applications

+24.3%

Interview Lift

719

Avg Prosecution Days

Based on 931 resolved cases, 2023–2026

1.1%

§101 Eligibility

24.4%

§102 Novelty

23.0%

§103 Obviousness

31.4%

§112 Clarity

App #	Title	Status	Assignee
18390137	INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF	Non-Final OA	Takeda Pharmaceutical Company Limited
18407245	ASH1L INHIBITORS AND METHODS AND TREATMENT THEREWITH	Non-Final OA	The Regents of the University of Michigan
18746981	PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS	Non-Final OA	Xenon Pharmaceuticals Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.